Virus de l'hépatite B :Réplication et mécanismes d'action des antiviraux

Virologie

Volumn 1, Issue 3, 1997, Pages 197-215

  Zoulim, F ^a,b   Trepo C ^a,b  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

Author keywords

Hepatitis B virus; Nucleoside analogs; Reverse transcriptase; Vaccine therapy

Indexed keywords

EID: 0000543639     PISSN: 12678694     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Ann Rev Biochem 1987 ; 56 :651-93.
2. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985 ; 317 :489-95.
3. Schlicht HJ, Salfeld J, Schaller H. The duck hepatitis B virus pre-C region encodes a signal sequence which is essential for synthesis and secretion of processed core proteins but not for virus formation. J Virol 1987 ; 61 :3701-9.
4. Chang LJ, Hirsch RC, Ganem D, Varmus HE. Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase. J Virol 1990 ; 64 :5553-8.
5. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-S sequence. J Virol 1984 ; 52 :396-402.
6. Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral replication in vivo. J Virol 1994 ; 68 :2026-30.
7. Schaller H, Fischer M. Transcriptionnal control of hepadnavirus gene expression. In :Current topics in microbiology and immunology. Hepadnaviruses. Molecular biology and pathogenesis. Mason W.S. and Seeger C., Eds. Springer-Verlag, Berlin, 1991 ;41-60.
8. Schek N, Fisher M, Schaller H. The hepadnaviral X protein. In :Molecular biology of the hepatitis B virus. Mc Lahlan A, Ed. CRC press, Florida, 1991 :181-92.
9. Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 1993 ; 361 :742-5.
10. Huang J, Kwong J, Sun E, Liang T. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J Virol 1996 ; 70 :5582-91.
11. Summers J. Three recently described animal virus models for human hepatitis B virus. Hepatology 1981 ; 1 :179-83.
12. Zoulim F, Seeger C, Trépo C. Modèles expérimentaux d'étude des hépadnavirus et des stratégies antivirales. Gastroentérol Clin Biol 1995 ; 19 :161-71.
13. Tuttleman J, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells. Cell 1986 ; 47 :451-60.
14. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986 ; 232 :477-84.
15. Junker-Niepmann M, Bartenschlager R, Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J 1990 ; 9 :3389-96.
16. Bartenschlager R, Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J 1992 ; 11 :3413-20.
17. Wang GH, Seeger C. The reverse transcriptase of hepatitis B virus acts a protein primer for viral DNA synthesis. Cell 1992 ; 71 :633-70.
18. Wang G, Zoulim F, Leber E, Kitson J, Seeger C. The role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses. J Virol 1994 ; 68 :8437-42.
19. Zoulim F, Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 1994 ; 68 :6-13.
20. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product :domain structure and RNAseH activity. J Virol 1990 ; 64 :613-20.
21. Zoulim F, Wang G, Seeger C. Methods for the purification of enzymatically active reverse transcriptase of duck hepatitis B virus. In :Viral hepatitis and liver disease. Proceedings of the International symposium on viral hepatitis and liver disease. Tokyo, May 10-14, 1993. K. Nishioka, H. Suzuki, S. Mishito, T. Oda eds. 1994 :97-100.
22. Mason WS, Taylor JM. Experimental systems for the study of hepadnavirus and hepatitis delta virus infections. Hepatology 1989 ; 9 :635-45.
23. Chisari F. Hepatitis B virus transgenic mice :insights into the virus and the disease. Hepatology 1995 ; 22 :1316-25
24. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the healthy HBs Ag carrier state. Hepatology 1987 ; 7 :758-63.
25. Popper H, Shafritz DA, Hoofnagle JH. Relation of the hepatitis B virus carrier state to hepatocellular carcinoma. Hepatology 1987 ; 7 :764-72.
26. Zoulim F, Trépo C. Virologie de l'hépatite B. Encycl Méd Chir (Elsevier, Paris). Hépatologie, 7-015-B-30, 1996, 19 p.
27. Zoulim F, Mimms L, Floreani M, et al. New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. J Clin Microbiol 1992 ; 30 :1111-9.
28. Lamelin J, Zoulim F, Trépo C. Lymphotropism of hepatitis B and C viruses:an update and a new comer. Int J Clin Lab Res 1995 ; 25 :1-6.
29. Zoulim F, Vitvitski L, Bouffard P, et al. Detection of pre-S1 proteins in peripheral blood mononuclear cells from patients with HBV infection. J Hepatol 1991 ; 12 :150-6.
30. Kock J, Theilmann L, Galle P, Schlicht H. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology 1996 ; 23 :405-13.
31. Chisari F. Analysis of hepadnavirus gene expression, biology, and pathogenesis in the transgenic mouse. Current Topics in Microbiology 1991 ; 168 :85-101.
32. Rehermann B, Ferrari C, Pasquinelli C, Chisari F. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Medicine 1996 ; 2 :1104-8.
33. Rehermann B, Chang K, McHutchinson J, et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996 ; 70 :7092-102
34. Bertoletti A, Seite A, Chisari F, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994 ; 369 :407-10.
35. Marcellin P, Ouzan D, Degos F, et al. Randomized controlled trial of adenine arabinoside 5′-monophosphate in chronic active hepatitis B :comparison of the efficacy in heterosexual and homosexual patients. Hepatotogy 1989 ; 10 :328-31.
36. Perrillo R, Schiff E, Davis G, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990 ; 323 :295-301.
37. Boyd M, Safrin S, Kern E. Penciclovir :a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother 1993 ; 4 (Supplement 1) :3-11.
38. Cerenzia M, Fiume L, De Bernadi Venon W, et al. Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Hepatology 1996 ; 23 :657-61.
39. Fiume L, Di Stefano G, Busi C, et al. Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route. Hepatology 1995 ; 22 :1072-7.
40. Bridges E, Cheng Y. Use of novel b-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. In :Progress in liver diseases. Eds, Boyer, JL and Ockner, RK 1995 ; 13 :231-45.
41. Nair V, Jahnke T. Antiviral activities of isomeric dideoxynucleosides of D- and L-related stereochemistry. Antimicrobial Agents Chemother 1995 ; 39 :1017-29.
42. Doong SL, Tsai C-H, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991 ; 88 :8495-9.
43. Arts E, Wainberg M. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrobial Agents Chemother 1996 ; 40 :527-40.
44. De Clercq E. Antiviral agents :characteristic activity spectrum depending on the molecular target with which they interact. Ad Virus Res 1993 ; 42 :1-55.
45. Aguesse S, Dannaoui E, Wang Z, et al. An in vitro assay for the determination of the mechanism of inhibition of hepatitis B virus replication by nucleoside analogs and non nucleoside inhibitors. Proceedings of the IX triennal International symposium of viral hepatitis and liver disease. In press 1996.
46. Hill C, Hartnup M, Faraj M, et al. Polyoxometalates as inorganic anti-HIV1 compounds. Structure-activity relationships. In :Advances in Chemotherapy of Aids. Diasio, RB and Sommadossi, JP, editors. Pergamon Press, New York 1990 :33-41.
47. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution if HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992 ; 256 :1783-90.
48. Zoulim F, Dannaoui E, Borel C, et al. 2′,3′-dideoxy-b-L-5-fiuorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrobial Agents Chemother 1996 ; 40 :448-53
49. Severini A, Liu XY, Wilson J, Tyrell D. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-b-L-2′,3′-dideoxy-3′-thyacytidine. Antimicrob Agents Chemother 1995 ; 39 :1430-5.
50. Dienstag J, Perillo R, Schiff E, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995 ; 333 :1657-61.
51. Nowak M, Bonhoeffer S, Hill A, Boehme R, Thomas H, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996 ; 93 :4398-402.
52. Zoulim F, Aguesse S, Borel C, Trépo C, Cheng Y. 2′fluoro-5-methyl-b- L-arabinofuranosyluracil, a novel L-nucleoside analog, inhibits duck hepatitis B virus replication in primary hepatocytes and in vivo. Antiviral Res 1996 ; 30 :A24
53. Korba B, Boyd M. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrobial Agents Chemother 1996 ; 40 :1282-4.
54. Lin E, Luscombe C, Wang Y, Shaw T, Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrobial Agents Chemother 1996 ; 40 :413-8.
55. Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrobial Agents Chemother 1994 ; 38 :719-23.
56. Zoulim F, Dannaoui E, Trépo C. Inhibitory effect of penciclovir on the priming of hepadnavirus reverse transcription. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995 ; Abstract H13, p. 182.
57. Mason W, Cullen J, Saputelli J, et al. Characterization of the antiviral activity of 2′carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 1994 ; 19 :398-411.
58. Fourel I, Saputelli J, Schaffer P, Mason W. The carbocyclic analog of 2′-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J Virol 1994 ; 68 :1059-65.
59. Fourel I, Cullen J, Saputelli J, et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol 1994 ; 68 :8321-30.
60. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 1994 ; 47 :155-69.
61. Van Draanen N, Tisdale M, Parry N, et al. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrobial Agents Chemother 1994 ; 38 :868-71.
62. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis, B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996 ; 24 :711-3.
63. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996 ; 24 :714-7.
64. Chen C, Cheng Y. Delayed cytoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1989 ; 264 :11934-7
65. McKenzie R, Fried M, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chrome hepatitis B. N Engl J Med 1995 ; 333 :1099-105.
66. Cui L, Yoon S, Schinazi R, Sommadossi J. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-b- D-arabinofuranosyl)-5-iodouracil in human. J Clin Invest 1995 ; 95 :555-63.
67. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996 ; 348 :1212-5.
68. Saltzman R, Jarewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrobial Agents Chemother 1994 ; 38 :2454-7.
69. Trépo C, Jezek P, Atkinson G, Boon R. Efficacy of famciclovir in chronic hepatitis B :results of a dose finding study. Hepatology 1996 ; 24 :188A (abstract 247).
70. Krüger M, Tillmann H, Trautwein C, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation. A pilot study. Liver Transplant Surg 1996 ; 2 :253-62.
71. Guilhot S, Guidotti L, Chisari F. Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. J Virol 1993 ; 67 :7444-9.
72. Gilles P, Fey G, Chisari F. Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol 1992 ; 66 :3955-60.
73. Mancini M, Hadchouel M, Tiollais P, Pourcel C, Michel M. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice :a possible way of circumventing « nonresponse to HBsAg ». J Med Virol 1992 ; 39 :67-74.
74. Pol S, Driss F, Michel M, Nalpas B, Berthelot P, Bréchet C. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994 ; 344-2.
75. Schirmbeck R, Bohm W, Ando K, Chisari F, Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol 1995 ; 69 :5929-34.
76. Offensperger W, Offensperger S, Walter E, et al. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 1993 ; 12 :1257-62.
77. Scaglioni P, Melegari M, Wands J. Characterization of hepatitis B virus core mutants that inhibit viral replication. Virology 1994 ; 205 :112-20.
78. von Weizsäcker F, Blum H, Wands F. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from single DNA template. Biochem Biophys Res Comm 1992 ; 189 :743-8.